Novo Nordisk A/S (NYSE:NVO) Shares Sold by Penobscot Investment Management Company Inc.

Penobscot Investment Management Company Inc. lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 14.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 35,569 shares of the company’s stock after selling 5,850 shares during the period. Penobscot Investment Management Company Inc.’s holdings in Novo Nordisk A/S were worth $3,060,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of NVO. Victory Capital Management Inc. increased its stake in shares of Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock worth $5,410,000 after buying an additional 23,223 shares during the last quarter. Norman Fields Gottscho Capital Management LLC increased its position in shares of Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after purchasing an additional 19,870 shares during the last quarter. Bryn Mawr Capital Management LLC increased its position in shares of Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock worth $3,346,000 after purchasing an additional 30,420 shares during the last quarter. Versant Capital Management Inc bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $86,000. Finally, Talbot Financial LLC acquired a new position in Novo Nordisk A/S in the fourth quarter worth about $4,066,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Trading Down 2.3 %

Shares of NYSE:NVO opened at $73.57 on Wednesday. Novo Nordisk A/S has a fifty-two week low of $73.20 and a fifty-two week high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The company has a market cap of $330.15 billion, a PE ratio of 22.36, a P/E/G ratio of 0.90 and a beta of 0.42. The company’s 50-day moving average price is $83.01 and its 200 day moving average price is $99.94.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is presently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.